Press Releases
2024
Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
December 4, 2024
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab)
November 19, 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Verzenio® (abemaciclib) in Expanded Early Breast Cancer (EBC) Indication
October 28, 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for OMVOH® (mirikizumab) for adults with moderately to severely active ulcerative colitis (UC)
September 3, 2024
Health Canada Authorizes Lilly’s Ebglyss™ (lebrikizumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents 12 Years and Older
June 25, 2024
Lilly’s OLUMIANT® (baricitinib) Now Authorized in Canada for Adults with Severe Alopecia Areata
January 30, 2024
Jardiance® (empagliflozin) receives authorization from Health Canada for the treatment of adults with chronic kidney disease
January 23, 2024
2023
Lilly Announces Health Canada’s Authorization of Verzenio® (abemaciclib) Label Expansion
December 7, 2023
Lilly’s Omvoh TM (mirikizumab) Now Available in Canada - A First-In-Class Treatment For Adults With Moderately To Severely Active Ulcerative Colitis
October 17, 2023
Lilly Canada to Clean Up Shorelines and Be Citizen Scientists for Global Day of Service
September 28, 2023
Results from Lilly’s Landmark Phase 3 Trial of Donanemab Presented at Alzheimer’s Association Conference and Published in JAMA
July 17, 2023
2022
EMPA-KIDNEY Trial Showed Significant Benefit of Jardiance® (empagliflozin) in Reducing Kidney Disease Progression or Cardiovascular Death by 28% vs. Placebo in People Living with Chronic Kidney Disease
November 4, 2022
Verzenio® (abemaciclib) Receives Positive Reimbursement Recommendation from Canadian Agency for Drugs and Technologies in Health (CADTH) for Early Breast Cancer
October 31, 2022
Coast-to-Coast: Lilly Global Day of Service (LGDOS) Connects Canada with Impact & Purpose
October 6, 2022
Product Discontinuation Update: Glucagon Emergency Kit (Glucagon for injection, rDNA origin, DIN 02243297)
August 25, 2022
2021
Eli Lilly Canada Inc. issues voluntary recall of a single lot of GLUCAGON (Lot D239382A, DIN 02243297) due to potential loss of potency
September 25, 2021
Lilly’s SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
June 28, 2021
Lilly launches “The Leonard Award” as part of a global initiative commemorating the discovery of insulin 100 years ago
June 24, 2021
Notice of Compliance with Conditions granted for Retevmo™ (selpercatinib), the first therapy in Canada specifically for patients with advanced RET-driven lung and thyroid cancers
June 21, 2021
Lilly announces new clinical data from Verzenio and oral SERD programs at the American Society of Clinical Oncology annual meeting
June 14, 2021
Taltz® delivers more cumulative days with completely clear skin for adults with psoriasis compared to seven other biologics in novel network meta-analysis
April 30, 2021
Olumiant® showed significant improvements in the severity and extent of atopic dermatitis and other patient-reported outcomes in Phase 3 study analyses
April 30, 2021
Lilly presents new data on selpercatinib in advanced RET fusion-positive gastrointestinal and other cancers at 2021 American Association for Cancer Research (AACR) annual meeting
April 20, 2021
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
April 16, 2021
Taltz® (ixekizumab) approved by Health Canada for the treatment of pediatric patients (six to less than 18 years of age) with moderate- to severe plaque psoriasis
April 2, 2021
Emgality® (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
February 25, 2021
2020
Data from ACTT-2 trial of baricitinib in hospitalized COVID-19 patients supportive of the U. S. FDA EUA published in New England Journal of Medicine
December 19, 2020
Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
December 14, 2020
Ontario Brain Institute and Eli Lilly Canada collaborate to train future Canadian neuroscience leaders
November 12, 2020
Health Canada has approved Taltz® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA)
October 19, 2020
Baricitinib has significant effect on recovery time, most impactful in patients with COVID-19 requiring oxygen
October 16, 2020
Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer
September 24, 2020
Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease
September 22, 2020
Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial
September 17, 2020
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
September 16, 2020
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
September 8, 2020
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
June 19, 2020
Lilly begins a Phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients
June 18, 2020
EULAR 2020: Lilly shares new data for Olumiant® in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
June 10, 2020
EULAR 2020: Lilly’s Taltz® (ixekizumab) continues to show robust and consistent efficacy in psoriatic arthritis
June 5, 2020
Health Canada has approved Taltz® (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis)
February 11, 2020
Lilly and Incyte announce positive top-line results from the North American Phase 3 study (BREEZE-AD5) of oral selective JAK inhibitor baricitinib in patients with moderate- to severe atopic dermatitis
February 11, 2020
Ready for Rescue – New nasally administered glucagon for severe hypoglycemia available in Canada
January 23, 2020
2019
ACR 2019: Lilly presents 52-week head-to-head (SPIRIT-H2H) data from TALTZ® (ixekizumab) versus Humira® (adalimumab) trial in psoriatic arthritis
November 26, 2019
ACR 2019: Lilly presents positive new data from COAST-X, a Phase 3 study of TALTZ® (ixekizumab) in patients with non-radiographic axial spondyloarthritis
November 26, 2019
New head-to-head data show TALTZ® (ixekizumab) superiority versus TREMFYA® (guselkumab) in people with moderate to severe plaque psoriasis
October 10, 2019
Verzenio™ (abemaciclib) significantly extends life by a median of 9.4 months for women with HR+, HER2- advanced breast cancer in MONARCH 2 study
October 4, 2019
EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine
October 2, 2019
Lilly announces superiority of TALTZ® (ixekizumab) versus TREMFYA® (guselkumab) in delivering total skin clearance at week 12 in topline results from head-to-head (IXORA-R) trial in people living with moderate to severe plaque psoriasis
August 14, 2019
VERZENIO™ (abemaciclib) available in Canada for metastatic breast cancer
August 8, 2019
Lilly announces positive results for Emgality™ (galcanezumab) from the CONQUER study in patients who failed previous migraine preventive treatments
August 8, 2019
Lilly presents positive results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head (SPIRIT-H2H) superiority study in patients with active psoriatic arthritis at the European Congress of Rheumatology
June 14, 2019
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
June 10, 2019
Lilly’s mirikizumab met primary endpoint and key secondary endpoints in Phase 2 study, including reductions of gastrointestinal lesions
May 22, 2019
Lilly announces top-line Phase 3 results for baricitinib in patients with moderate to severe atopic dermatitis
February 4, 2019
2018
Lilly announces positive top-line results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head superiority study (SPIRIT-H2H) in patients with active psoriatic arthritis
December 17, 2018
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease
November 6, 2018
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
November 5, 2018
With availability of Olumiant™ (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
November 1, 2018
Lilly’s investigational dual GIP and GLP-1 receptor agonist shows significant reduction in HbA1c and body weight in people with type 2 diabetes
October 9, 2018
Health Canada approves Taltz® (ixekizumab) for treatment of active psoriatic arthritis
June 20, 2018
Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada
May 3, 2018
LARTRUVO™ (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults
January 24, 2018
2017
New concentrated insulin approved and available for Canadian patients
December 12, 2017
What matters most to Canadians living with rheumatoid arthritis?
October 26, 2017
Deeper than just skin, World Psoriasis Day spotlights the disease’s human impact
October 25, 2017
Acclaimed musician and former American Idol in Toronto for a special performance for children with type 1 diabetes
August 31, 2017
New report reveals little progress on 2014 WHO psoriasis recommendations
April 18, 2017
2016
Health Canada approves new indication for JARDIANCE™ (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease
August 11, 2016
Health Canada’s approval of Taltz™ (ixekizumab) brings targeted therapy to Canadians living with moderate-to-severe plaque psoriasis
June 21, 2016
JARDIANCE® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
June 14, 2016
Trulicity™, a once-weekly GLP-1 injectable medication, now available to help Canadians with type 2 diabetes manage their blood sugar
February 16, 2016